Orion Corporation is developing a budesonide-formoterol formulation combining budesonide as an anti-inflammatory agent and formoterol as a long-acting bronchodilator to expand the range of the inhalable Easyhaler® drug product family for treatment of asthma and COPD.
Based on the favorable pharmacokinetic study results of this Easyhaler-development programme Orion is planning to apply for a marketing authorisation for the combined budesonide-formoterol formulation. Orion currently estimates that the marketing authorisation application would be submitted in Europe during the first half of 2013.
President and CEO
SVP, Corporate Functions
Reijo Salonen, Senior Vice President, Research and Development (as of Monday 3 December)
tel. +358 50 966 3647
Jari Karlson, CFO
tel. +358 50 966 2883
Orionintie 1A, FI-02200 Espoo
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2011 amounted to EUR 918 million and the company had about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.